To explore the therapeutic efficacy and potential mechanisms of action of a new class of anti-atherosclerotic drugs, AGI-1067 was tested in several animal models of atherosclerosis. AGI-1067, a novel phenolic antioxidant, was well tolerated in a one-year study in hypercholesterolemic cynomolgus monkeys. It lowered LDLc by 41% and 90% at oral doses of 50 and 150 mg/kg, respectively, and increased HDLc by 107% at the higher dose. In contrast, another phenolic antioxidant, probucol, had a modest LDLlowering effect (15% at 250 mg/kg) while decreasing HDLc (37% at 150 mg/kg).
Probucol is a known lipophilic antioxidant with modest lipid-lowering properties. It is predominantly associated with lipoproteins in the plasma and has been shown to inhibit oxidative modification of LDL (Parthasarathy et al., 1986) . Probucol inhibits atherosclerosis in some animals (Daugherty and Roselaar, 1995) and has been evaluated in two clinical trials for its ability to decrease the complications of cardiovascular disease in patients with hypercholesterolemia. In the Probucol Quantitative Regression Swedish Trial (PQRST), it lowered cholesterol but did not induce atherosclerotic regression in the femoral artery (Johansson et al., 1995) . In the Fukuoka Atherosclerosis Trial (FAST), probucol lowered cholesterol and stopped progression of atherosclerotic plaques in carotid arteries. Probucol also reduced the incidence of cardiac events when compared to the control group despite lowering HDL cholesterol (Sawayama et al., 2002) . However, chronic clinical use of probucol has been limited since it lowers HDL cholesterol and causes QTc interval prolongation (Klein, 1981) .
In this paper, AGI-1067, a novel antioxidant, anti-inflammatory and lipidlowering agent that has anti-atherosclerotic properties is described. It is a metabolically stable derivative of probucol that was designed to retain favorable characteristics of probucol (antioxidant and modest lipid-lowering activity) while improving on its JPET/2002/48132 7 hematology. Blood was fractionated and cholesterol in the LDL and HDL fraction determined from week 8 until termination of study. Blood samples were taken by venepuncture; EDTA was used as an anticoagulant for the hematology samples, and lithium heparin was used for the clinical chemistry samples. At the end of the study the animals were euthanized by intravenous injection of sodium pentobarbitone. All animals were examined externally, then exsanguinated. Organs were weighed and then fixed in 10% formalin and evaluated for histopathology by a veterinary pathologist. Specifically, the left coronary was removed and fixed in formal calcium; the right coronary artery was fixed in situ. Samples of aortic arch and abdominal aorta were also fixed in formal calcium. Two transverse sections each of aortic arch and abdominal aorta were examined, as were two transverse sections of left and right coronary arteries. All tissues were wax embedded, cut at a nominal thickness of 5 µm, and stained with hematoxylin and eosin. Aortas and livers from some animals were also stained with Oil-Red-O to confirm the presence of fat. The histopathology was subject to peer review that was in good agreement with the original histopathologist's findings.
A scoring system was devised that took into account the severity and incidence of atherosclerosis in the coronary arteries and aortas. The atherosclerotic lesions were given a severity rating from 0-4 corresponding to none, minimal, slight, moderate and severe.
The incidence of atherosclerosis was determined as the number of animals per group that had lesions that fell into a particular severity category. The total atherosclerosis score was derived by taking the sum of the incidence X severity for all the animals in a group.
For example, the probucol (150 mg/kg/day) group had one animal with minimal (1 X 1=1), one with slight (2 X 1=2), one with moderate (1 X 3=3) and one with severe (1 X This article has not been copyedited and formatted. The final version may differ from this version.
JPET Fast Forward. Published on March 6, 2003 as DOI: 10.1124 at ASPET Journals on October 2, 2017 jpet.aspetjournals.org Downloaded from 4=4) atherosclerotic lesions in the left coronary arteries for a total score of "10" (1 + 2 + 3 + 4 = 10) for the group.
LDLr -/-and ApoE -/-Mouse Atherosclerosis Studies
Six-week old LDL-receptor (LDLr) -/-mice and ApoE -/-mice (Jackson Laboratories, Bar Harbor, ME) backcrossed for six generations to the C57BL/6 background were used for these studies. For the LDLr -/-study, three groups of twenty mice each received a high fat diet (Harlan Teklad, Indianapolis, IN; TD 88051, containing 1.25% cholesterol and 0.5% sodium cholate) alone or with AGI-1067 or probucol added for 12 weeks. Blood was sampled after 2 and 12 weeks. For the ApoE -/-mouse atherosclerosis study, three groups of 15 animals each received high fat chow (Harlan Teklad, (TD 97073 containing 1.25% cholesterol)) for 12 weeks with or without AGI-1067 or probucol added to the chow at a final concentration of 0.09% wt/wt. In both studies, AGI-1067 or probucol was added to the chow to deliver approximately 150 mg/kg/day. The mice were then euthanized by halothane overdose and their circulatory systems perfused with 4% paraformaldehyde. The aortas were excised, fixed overnight in 4% paraformaldehyde, and adventitial fat removed. Computer-assisted morphometery of en face lesions was used to assess the extent of atherosclerosis. Aortas from LDLr -/-mice were further evaluated for cholesterol ester content by gas chromatography with flame ionization detection as described previously (Daugherty et al., 1997) .
Plasma Lipoprotein Profiling and Cholesterol Determination
Plasma was fractionated by fast-phase liquid chromatography (FPLC) and cholesterol levels in the different lipoprotein fractions determined by an enzymatic assay as described (Innis-Whitehouse et al., 1998) . This article has not been copyedited and formatted. The final version may differ from this version. Duplicate samples were prepared; one set was used to quantitate the amount of LDL captured by using biotinylated-detecting anti-ApoB antibodies (YE-1 for rabbit samples and MB24 for monkey samples, generous gift from J. Witztum). The second set of samples was used to quantitate the amount of LDL being oxidized by using a biotinylated antibody to oxidatively-modified LDL (EO6, a generous gift from J. Witztum). E06 is a monoclonal autoantibody isolated from ApoE -/-mice (Palinski et al, 1996) . E06 was shown to recognize oxidatively-modified LDL in vitro and in atherosclerotic lesions in humans and animals (Palinski et al, 1996) . E06 recognizes oxidized phospolipid, 1-palmitoyl-2-(5-oxovaleroyl)-phosphatidyl-choline (POPVC) (Horkko et al, 1999) . A luminescence signal (relative light units) was generated from streptavidin, which was conjugated to Aqualite bound to biotinylated antibodies (Sealite Science, Norcross, GA) and recorded with a Dynex luminometer (Dynex Technologies, Chantilly, VA). The data is reported as an oxidation score, which is the ratio of relative light units of E06 signal (20 hr oxidation/no oxidation) and YE-1 or MB 24 signal ( 20 hr oxidation/no oxidation).
In Vivo Lipopolysaccharide (LPS) Challenge Study
Eleven six-week old C57BL/6 mice were anesthetized with ketamine (100 mg/kg) and xylazine (10 mg/kg, i.p.). Research Associates, Sarasota, FL) containing AGI-1067, probucol or placebo were implanted subcutaneously for an average daily dose of 133 mg/kg/day. Four mice received AGI-1067, four received probucol and three received the placebo in this manner.
After one week, the mice were challenged with an intraperitoneal injection of 1 mg/kg LPS (Sigma Chemicals, St. Louis, MO) and sacrificed 2 hr later. Lungs were removed and immediately frozen in liquid nitrogen for RNA extraction.
Northern Blot Analysis
Total RNA was extracted from mouse lungs using TriPure Isolation Reagent (Roche Applied Science, Indianapolis, IN). For Northern blot analysis, 30 µg total RNA was separated on a 1% denaturing formaldehyde agarose gel, then transferred to a nylon membrane. Membranes were hybridized with 32 P-labelled probes to mouse VCAM-1, MCP-1/JE and β-actin as described previously (Marui et al, 1993) . Laser densitometry and digital analysis of scanned images were used for quantitation of autoradiograms.
Cell Culture and Enzyme Linked Immunosorbent Assay (ELISA)
VCAM-1, ICAM-1, and E-selectin expressed on the surface of activated human aortic endothelial cells (HAECs) (Clonetics, Inc., Walkersville, MD) and MCP-1 secreted into the cell media were assessed by ELISA. HAECs passaged less than eight times were plated onto 24-well tissue culture dishes at a density of 3.6 -4.0 X 10 4 cells/ml in endothelial growth media + 10% fetal bovine serum (FBS) (Clonetics, Inc.). The media was changed 24 hr later and TNF-α (10 units/well) was added either with AGI-1067 (2.5- 
Statistical Analysis
Statistical significance was determined by ANOVA with comparisons made using 
Results:

Effects of AGI-1067 in Hypercholesterolemic Monkeys
AGI-1067 is a novel phenolic antioxidant ( Figure 1 ) that lowers LDLc in multiple species (Meng et al, 2002) . Given these properties, we hypothesized that AGI-1067 may have utility in CAD. To address this assumption, AGI-1067 was evaluated in hypercholesterolemic cynomolgus monkeys at oral doses of 50 and 150 mg/kg/day and results were compared to probucol (150 and 250 mg/kg/day) in a yearlong study. AGI-1067 dose-dependently reduced plasma cholesterol levels. In contrast, probucol had no effect at 150 mg/kg/day and a modest cholesterol-lowering effect at 250 mg/kg/day ( Figure 2 ). Total cholesterol levels at the end of the study expressed as the percent change from pre-treatment levels (-1 week) were 112 + 61% for the control group; 14 + 15% and -39 + 13% for the 50 and 150 mg/kg/day AGI-1067 groups, respectively; and 84 + 30%
and 130 + 24% for the 150 and 250 mg/kg/day probucol groups, respectively.
Triglyceride levels were not significantly affected by either compound in this study.
Evaluation of plasma cholesterol levels in the LDL and HDL fractions after 1 year of therapy revealed that LDLc levels in the AGI-1067-treated groups were reduced by 41%
and 90% (p<0.05) at the 50 and 150 mg/kg/day doses, respectively, when compared with vehicle controls (Figure 3a ). HDLc levels were no different than the vehicle group at the 50 mg/kg/day dose and were increased 107% (p<0.05) at the 150 mg/kg/day when compared with vehicle controls (Figure 3b ). In contrast, probucol did not have a statistically significant effect on LDLc levels and decreased HDLc by 37% at 150 mg/kg/day and had no effect at 250 mg/kg/day when compared to vehicle controls.
Semiquantitative histopathological analyses of cross sections of the aortas and
This article has not been copyedited and formatted. The final version may differ from this version. mg/kg/day, respectively. In a similar study in rabbits, LDL from hypercholesterolemic rabbits treated with AGI-1067 or probucol at a dose of 150 mg/kg/day demonstrated similar ability to protect LDL from ex vivo oxidation. These data suggest that additional properties of AGI-1067 beyond its ability to protect LDL from oxidation are likely to contribute to the differential inhibitory effects of the two compounds on atherosclerosis progression.
Inhibition of Atherosclerosis in the Absence of a Lipid-lowering Effect
To separate the lipid-lowering effects of AGI-1067 from any direct vascular antiinflammatory effects, the compound was further evaluated using a more quantitative approach in two transgenic mice models, the LDLr -/-and the ApoE -/-mice. AGI-1067
did not lower lipids in the LDLr -/-mice and caused a transient lipid lowering effect in ApoE -/-mice; probucol caused transient lipid lowering in both models (Table 1) . 
In Vivo Anti-inflammatory Properties
The potential in vivo anti-inflammatory effects of AGI-1067 were investigated in a murine model of LPS-induced acute inflammation that results in upregulation of proinflammatory genes. When lungs from non-LPS, placebo-treated mice were evaluated, there was no expression of VCAM-1 or MCP-1 (as assessed by Northern analysis), whereas mRNAs from both these genes were increased 2 hr after LPS-challenge of placebo-treated mice (Figure 8a and b). Prior treatment with AGI-1067 at ~133 mg/kg/day for one week significantly inhibited the LPS-induced increase in lung VCAM-1 and MCP-1 mRNA levels. Probucol, at the same dose, had a modest and more variable inhibitory effect. These data corroborate and extend our in vitro studies by demonstrating that AGI-1067 acts as an anti-inflammatory agent in vivo by inhibiting the induction of the pro-inflammatory genes VCAM-1 and MCP-1 at plasma levels that are well tolerated.
Effects on Redox-Mediated Processes in Human Aortic Endothelial Cells (HAECs)
In order to determine whether AGI-1067 directly affects the cells of the blood vessel wall, the compound was evaluated in cultured HAECs for its effects on redoxsensitive inflammatory gene expression. AGI-1067 (2.5-10 µM) added to HAECs concomitantly with TNF-α for 16 hr inhibited VCAM-1 cell surface expression (IC 50 = 6 µM, average of 3 experiments). AGI-1067 had no effect on the cell surface expression of respectively; probucol also had no effect on the inducible expression of these genes (data not shown). These data demonstrate that AGI-1067 can act directly on endothelial cells to inhibit redox-sensitive processes such as the induction of inflammatory genes.
This article has not been copyedited and formatted. The final version may differ from this version. The anti-atherosclerotic effects of AGI-1067 were also demonstrated in two commonly used models of hypercholesterolemia-induced atherosclerosis, the LDLr -/-mouse and the ApoE -/-mouse (Ishibashi et al, 1994; Zhang et al, 1992) . AGI-1067 had no effect on cholesterol levels in the LDLr -/-mice and transient effects in the ApoE -/-mice. The lack of a sustained lipid-lowering effect in these mice may be due to the lack of the LDL receptor in the case of LDLr -/-mice and its down regulation in ApoE -/-mice that occurs after prolonged exposure to high cholesterol levels (Brown and Goldstein, 1975) . Irrespective of the mechanism, the inability of AGI-1067 to lower plasma cholesterol levels in these two mouse strains allowed for a direct assessment of the compounds anti-atherosclerotic properties independent of its lipid-lowering effects.
In spite of having either no or transient lipid-lowering effects in these mice, AGI-1067 still significantly inhibited atherosclerosis to a greater extent than probucol, which had This article has not been copyedited and formatted. The final version may differ from this version. modest lipid-lowering effects in these models. We report a modest anti-atherosclerotic effect of probucol in LDLr -/-and ApoE -/-mice, in apparent contradiction to several reported studies that showed a pro-atherosclerotic effect of the drug in these same mouse strains (Zhang et al, 1997; Moghadasian et al, 1999) . One possible explanation for these disparate results is the 5-11X lower dose of probucol used in our study, thereby suggesting that part of the pro-atherosclerotic effect seen in these other studies may be caused by toxicity due to high plasma levels.
These data led us to surmise that the anti-atherosclerotic properties observed in these studies may be due to AGI-1067's anti-inflammatory properties. This was directly Under the conditions used in this study, probucol was less active in inhibiting TNF-α-induced VCAM-1, MCP-1 and E-selectin expression in cultured endothelial cells when compared to AGI-1067. Reported effects of probucol on the expression of these genes vary (Kaneko et al, 1996; Tanaka et al, 1998; Zapolska-Downer et al, 2001 ). This may be due to differences in protocol such as method of activation, cell density, cell type used, drug concentration and length of exposure. The greater activity of AGI-1067 when compared to probucol in inhibiting redox-sensitive inflammatory gene expression may be due to its enhanced cell permeability. The carboxylic acid in the side chain of AGI-1067
would be expected to decrease its lipophilicity compared to probucol; this may increase its cell permeability and access to intracellular sites of redox regulation relative to probucol. This is consistent with the observation that in endothelial cell culture AGI-1067 partitions with the cellular fraction whereas, probucol is predominantly associated with the media (unpublished data). propensity to partition with lipoproteins in the plasma. Thus the ability of AGI-1067 to protect LDL from oxidation may contribute to its anti-atherosclerotic properties, but does not explain the differential pharmacological effects of AGI-1067 and probucol.
Consistent with its in vitro
The pharmacology data presented here suggest that AGI-1067 works by a novel mechanism that is distinct from statins, which are currently the therapeutic agents of choice for CAD patients. Whereas, statins reduce the risk of developing CAD primarily by decreasing LDLc, AGI-1067 is anticipated to inhibit the progression of the disease and possibly reverse it by acting directly on the vessel wall to protect it from oxidative damage. As such, AGI-1067 belongs to a new class of compounds known as vascular protectants that are predicted to be efficacious in patients with CAD that do not have elevated cholesterol levels as well as those that are at risk for CAD due to other risk factors such as diabetes and hypertension.
In summary, AGI-1067 inhibited atherosclerosis in primate and mouse models of hypercholesterolemia-induced atherosclerosis. Furthermore, in mice, it inhibited atherosclerosis by a mechanism unrelated to its lipid-lowering properties. AGI-1067 was distinguished from probucol in these studies by its superior lipid-modulating, antiinflammatory and anti-atheroslcerotic properties and its ability to inhibit redox-sensitive processes in vascular wall cells. These data support the central role of abnormal redoxsignalling in the pathogenesis of atherosclerosis and taken together with promising clinical data, suggest that AGI-1067 may be a novel and safe therapeutic agent for CAD as well as restenosis after percutaneous coronary intervention.
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